Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

2 terminated/withdrawn out of 14 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

43%

6 trials in Phase 3/4

Results Transparency

0 of 10 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

5(45.5%)

Phase 2

4(36.4%)

Phase 1

1(9.1%)

Phase 4

1(9.1%)

11Total

Phase 3(5)

Phase 2(4)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (14)

Showing 14 of 14 trials

NCT00910819Completed

Tumour Registry Colorectal Cancer

Role: collaborator

NCT01351584Completed

Tumour Registry Breast Cancer

Role: collaborator

NCT07124884Phase 2Not Yet Recruiting

5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab

Role: collaborator

NCT02578368Phase 3Completed

Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Role: collaborator

NCT03811418Phase 3Withdrawn

A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer

Role: collaborator

NCT02248571Phase 4Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab

Role: collaborator

NCT00868634Phase 3Completed

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

Role: collaborator

NCT00085163Phase 3Completed

Celecoxib Combined With Fluorouracil and Leucovorin in Treating Patients With Resected Stage III Adenocarcinoma (Cancer) of the Colon

Role: collaborator

NCT00911222Completed

Epidemiological EMESIS-Registry